A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus (SELENE 1)
A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity Without Type 2 Diabetes Mellitus (SELENE 1)
- Obesity or Overweight
At a glance
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- AstraZeneca
- Enrolment target
- 2,500
- Started
- 19 August 2026
- Main results due (estimated)
- 11 August 2028
- Study ends (estimated)
- 21 May 2029
- Allocation
- Randomized
- Design
- Parallel
- Purpose
- Treatment
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Sites
- 220 · 14 in India
- First posted
- 25 August 2026
- Registry updated
- 30 October 2026
International, multi-centre, randomised, double-blind, placebo-controlled, parallel-group
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied. Healthy volunteers are not accepted.
Age groups: adult, older adult.
These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Males \& females (inclusive of all gender identities) age ≥18 years * BMI ≥30 kg/m2 OR BMI ≥27 kg/m2 with at least one of the following weight related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, heart failure, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, osteoarthritis of the knee, or stress urinary incontinence * Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation * History of at least one self-reported unsuccessful attempt to lose body weight in their lifetime Exclusion Criteria: * Obesity primarily caused by other endocrine disorders * History of Type 1 or Type 2 Diabetes Mellitus, HbA1c ≥6.5% (48 mmol/mol), and/or treatment with glucose-lowering agent(s) within 3 months prior to Screening * Significant hepatobiliary disease and/or any of the following results at Screening: * ALT ≥ 3.0 × ULN * AST ≥ 3.0 × ULN * TBL \> 1.5 × ULN (except for cases of known Gilbert's Syndrome) * Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation.
What this study is about
In the sponsor’s own words, from the registry.
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
Read the detailed description
This is a Phase III, global, randomised, parallel-group, double-blind, multicentre study to assess the efficacy and safety of AZD6234 compared with placebo, administered SC once weekly in adults with obesity or overweight with at least one weight-related comorbidity without T2DM. Eligible participants will be randomized to either receive AZD6234 or matching placebo respectively.
Keywords: Obesity · Overweight · AZD6234 · Lenbelintide
What participants receive
- Experimental
AZD6234 Dose 1
AZD6234 Dose 1
Drug: Lenbelintide
- Experimental
AZD6234 Dose 2
AZD6234 Dose 2
Drug: Lenbelintide
- Placebo comparator
Placebo
Matching placebo
Drug: Placebo
Interventions
LenbelintideDrug
Also known as AZD6234
IMP injected subcutaneously, once a week. Unit dose strength as per CSP.
PlaceboDrug
Placebo matching IMP dose injected subcutaneously, once a week.
What the study measures
Primary outcomes
Percent change in body weight from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 as compared to placebo in percent body weight change
Time frame: 68 weeks
Secondary outcomes
Absolute change in weight (kg) from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 as compared to placebo on absolute change in weight
Time frame: 68 weeks
Achievement of at least 5 % body weight loss from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 as compared to placebo in body weight loss of at least 5%
Time frame: 68 weeks
Achievement of at least 10% body weight loss from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 as compared to placebo in body weight loss of at least 10%
Time frame: 68 weeks
Change in waist circumference (cm) from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 as compared to placebo on waist circumference change
Time frame: 68 weeks
Percent change in triglycerides from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 as compared to placebo on triglycerides percent change
Time frame: 68 weeks
Change in systolic blood pressure (mmHg) from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 as compared to placebo on systolic blood pressure change
Time frame: 68 weeks
Percent change in fat mass from baseline at 68 weeks of treatment measured by DXA in the DXA Sub-Study subset
Body Composition Sub-study: To evaluate the effect of AZD6234 as compared to placebo on body composition change in the DXA subset of participants
Time frame: 68 weeks
Who is running it
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry
- Responsible party
- The sponsor
- Organisation
- AstraZeneca
- Data monitoring committee
- No
- US FDA-regulated drug
- Yes
- US FDA-regulated device
- No
- Sponsor's study ID
- D8750C00014
- Other IDs
- 2025-523379-41-00, 159494, 2025
Study sites(220)
Research Site
Bhubaneswar, India
Suspended
Research Site
Coimbatore, India
Not yet recruiting
Research Site
Hyderabad, India
Not yet recruiting
Research Site
Indore, India
Not yet recruiting
Research Site
Jaipur, India
Not yet recruiting
Research Site
Jodhpur, India
Not yet recruiting
Research Site
Kochi, India
Suspended
Research Site
Kolkata, India
Not yet recruiting
Research Site
Noida, India
Not yet recruiting
Research Site
Pune, India
Not yet recruiting
Research Site
Pune, India
Not yet recruiting
Research Site
Siliguri, India
Not yet recruiting
Research Site
Surat, India
Not yet recruiting
Research Site
Vijayawada, India
Not yet recruiting
Research Site
Dothan, Alabama, United States
Recruiting
Research Site
Escondido, California, United States
Recruiting
Research Site
Clearwater, Florida, United States
Recruiting
Research Site
Stockbridge, Georgia, United States
Recruiting
Research Site
Champaign, Illinois, United States
Recruiting
Research Site
Chicago, Illinois, United States
Recruiting
Research Site
Ames, Iowa, United States
Recruiting
Research Site
Kansas City, Missouri, United States
Recruiting
Research Site
Rocky Mount, North Carolina, United States
Recruiting
Research Site
Statesville, North Carolina, United States
Recruiting
Research Site
Fargo, North Dakota, United States
Recruiting
Research Site
Columbus, Ohio, United States
Recruiting
Research Site
Tulsa, Oklahoma, United States
Recruiting
Research Site
Philadelphia, Pennsylvania, United States
Recruiting
Research Site
Smithfield, Pennsylvania, United States
Recruiting
Research Site
Kingsport, Tennessee, United States
Recruiting
Research Site
Houston, Texas, United States
Recruiting
Research Site
Sugar Land, Texas, United States
Recruiting
Research Site
Waco, Texas, United States
Recruiting
Research Site
Buenos Aires, Argentina
Recruiting
Research Site
Buenos Aires, Argentina
Recruiting
Research Site
Ciudad de Buenos Aires, Argentina
Recruiting
Research Site
Mendoza, Argentina
Recruiting
Research Site
Rosario, Argentina
Recruiting
Research Site
Botany, Australia
Recruiting
Research Site
Camberwell, Australia
Recruiting
Showing 40 of 220 sites. 76 recruiting, 139 not recruiting and 5 cancelled; 14 in India. Not recruiting covers sites not yet open, finished enrolling, completed or paused; cancelled covers sites withdrawn before opening or stopped for good.
References and data sharing
- Participant data shared
- Yes
- What is shared
- Study protocol, Sap
- When
- AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
- Access
- When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
- Where
- https://vivli.org/
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Source: ClinicalTrials.gov record NCT07784725, status verified October 2026. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Interested in this study?
Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.